drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous CAR T cells)
drug_description
Autologous, genetically modified CAR T-cell therapy made from PD-1–positive T cells transduced via lentivirus to express a TROP2-directed CAR plus an additional enhanced receptor; administered as a one-time IV infusion for TROP2-expressing advanced solid tumors.
nci_thesaurus_concept_id
C202235
nci_thesaurus_definition
A preparation of autologous programmed cell death protein 1 (PD-1; PDCD1; CD279)-positive T-lymphocytes transduced with a lentivirus expressing a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) trophoblast cell surface protein 2 (trophoblast antigen 2; tumor-associated calcium signal transducer 2; TROP2; TROP-2; TACSTD2; GA733-1; M1S1), with potential immunostimulating and antineoplastic activities. Upon administration, autologous TROP2-CAR-transduced PD-1-positive T-cells T60c target, bind to and induce selective cytotoxicity in TROP2-expressing tumor cells. TROP2 is a transmembrane protein overexpressed in various tumors. Its expression is associated with enhanced tumor aggressiveness, metastasis, drug resistance and increased tumor cell survival.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous PD-1-positive T cells are transduced with a lentiviral vector to express a TROP2-directed chimeric antigen receptor plus an enhancement receptor. After infusion, the CAR recognizes TROP2 on tumor cells and triggers CD3zeta/costimulatory signaling, leading to T-cell activation, cytokine release, and cytotoxic killing of TROP2-expressing cancer cells; the enhancement receptor is intended to improve function within the tumor microenvironment.
drug_name
T60c
nct_id_drug_ref
NCT06082557